Kapadia S, Gudiwada SP, Kaji AH, Chlebowski RT, et al. Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result? Breast J 2020 Oct 1. doi: 10.1111/tbj.14068.
PMID: 33001531